PT  - JOURNAL ARTICLE
AU  - Takita, Morihito
AU  - Matsumura, Tomoko
AU  - Yamamoto, Kana
AU  - Yamashita, Erika
AU  - Hosoda, Kazutaka
AU  - Hamaki, Tamae
AU  - Kusumi, Eiji
TI  - Regional Difference in Seroprevalence of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing
AID  - 10.1101/2020.06.03.20121020
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.03.20121020
4099  - http://medrxiv.org/content/early/2020/06/04/2020.06.03.20121020.short
4100  - http://medrxiv.org/content/early/2020/06/04/2020.06.03.20121020.full
AB  - The serosurvey is an alternative way to know the magnitude of the population infected by coronavirus disease 2019 (COVID-19) since the expansion of capacity of the polymerase chain reaction (PCR) to detect the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was delayed. We herein report seroprevalence of COVID-19 accessed in the two community clinics in Tokyo. The point-of-care immunodiagnostic test was implemented to detect the SARS-CoV-2 specific IgG antibody in the peripheral capillary blood. The overall positive percentage of SARS-CoV-2 IgG antibody is 3.83% (95% confidence interval: 2.76-5.16) for the entire cohort (n =1,071). The central Tokyo of 23 special wards exhibited a significantly higher prevalence compared to the other area of Tokyo (p =0.02, 4.68% [95%CI: 3.08-6.79] versus 1.83 [0.68-3.95] in central and suburban Tokyo, respectively). The seroprevalence of the cohort surveyed in this study is low for herd immunity, which suggests the need for robust disease control and prevention. A community-based approach, rather than state or prefectural levels, is of importance to figure out profiles of the SARS-COV-2 outbreak.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThe present study was performed by intramural funding of Navitas Clinic. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Navitas Clinic approved the present study (Approval Number: NC2020-01).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request to protect the privacy of study participants.